Novavax Company Profile (NASDAQ:NVAX)

About Novavax (NASDAQ:NVAX)

Novavax logoNovavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:NVAX
  • CUSIP: 67000210
  • Web:
  • Market Cap: $304.39 million
  • Outstanding Shares: 294,183,000
Average Prices:
  • 50 Day Moving Avg: $1.14
  • 200 Day Moving Avg: $1.06
  • 52 Week Range: $0.73 - $1.78
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.91
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $21.04 million
  • Price / Sales: 14.68
  • Book Value: ($0.20) per share
  • Price / Book: -5.25
  • EBITDA: ($186,640,000.00)
  • Net Margins: -1,006.00%
  • Return on Equity: -787.38%
  • Return on Assets: -53.89%
  • Debt-to-Equity Ratio: -5.37%
  • Current Ratio: 3.54%
  • Quick Ratio: 3.54%
  • Average Volume: 5.80 million shs.
  • Beta: 1.97
  • Short Ratio: 5.54

Frequently Asked Questions for Novavax (NASDAQ:NVAX)

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) announced its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.16) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.16). The company had revenue of $6.70 million for the quarter, compared to analyst estimates of $6.15 million. Novavax had a negative net margin of 1,006.00% and a negative return on equity of 787.38%. Novavax's quarterly revenue was up 168.0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.29) EPS. View Novavax's Earnings History.

Where is Novavax's stock going? Where will Novavax's stock price be in 2017?

8 brokerages have issued 12-month target prices for Novavax's stock. Their forecasts range from $1.50 to $12.00. On average, they expect Novavax's stock price to reach $3.35 in the next year. View Analyst Ratings for Novavax.

What are analysts saying about Novavax stock?

Here are some recent quotes from research analysts about Novavax stock:

  • 1. According to Zacks Investment Research, "NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. " (8/19/2017)
  • 2. Cantor Fitzgerald analysts commented, "Important RSV vaccine data to be released next Monday. NVAX plans to host a conference call on Monday, July 24, at 4:30pm EDT, on which top-line data from the E-205 Phase 2 clinical trial of the RSV vaccine candidate in older adults will be discussed. The company’s press release notes that an update of the ongoing pivotal Prepare trial of the vaccine candidate in pregnant women will also be provided. Of the two programs, we believe the former is likely to be the greater value creator and, if the data are encouraging, could provide a catalyst for renewed investor interest in the stock." (7/21/2017)
  • 3. Chardan Capital analysts commented, "The company is at a pre-commercialization stage, although it does recognize revenue from research and development collaborations. Reported revenue in Q4 was $5.4M, which was inline with consensus." (2/28/2017)

Are investors shorting Novavax?

Novavax saw a decline in short interest in September. As of September 29th, there was short interest totalling 47,385,568 shares, a decline of 12.6% from the September 15th total of 54,225,598 shares. Based on an average daily volume of 4,572,248 shares, the days-to-cover ratio is presently 10.4 days. Approximately 16.3% of the shares of the company are short sold.

Who are some of Novavax's key competitors?

Who are Novavax's key executives?

Novavax's management team includes the folowing people:

  • James Francis Young Ph.D., Independent Chairman of the Board
  • Stanley C. Erck, President, Chief Executive Officer, Director
  • Barclay A. Phillips, Chief Financial Officer, Senior Vice President, Treasurer
  • Gregory M. Glenn M.D., President, Research and Development
  • John A. Herrmann III, Senior Vice President, General Counsel, Corporate Secretary
  • John J. Trizzino, Senior Vice President - Commercial Operations
  • James F. Cummings, Vice President - Clinical Development and Translational Medicine
  • Rajiv I. Modi Ph.D., Director
  • Gail Koziara Boudreaux, Independent Director
  • Richard H. Douglas Ph.D., Independent Director

How do I buy Novavax stock?

Shares of Novavax can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novavax's stock price today?

One share of Novavax stock can currently be purchased for approximately $1.05.

MarketBeat Community Rating for Novavax (NASDAQ NVAX)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  242 (Vote Outperform)
Underperform Votes:  167 (Vote Underperform)
Total Votes:  409
MarketBeat's community ratings are surveys of what our community members think about Novavax and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Novavax (NASDAQ:NVAX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $3.35 (219.05% upside)
Consensus Price Target History for Novavax (NASDAQ:NVAX)
Price Target History for Novavax (NASDAQ:NVAX)
Analysts' Ratings History for Novavax (NASDAQ:NVAX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/6/2017Seaport Global SecuritiesReiterated RatingNeutralN/AView Rating Details
8/9/2017Ladenburg Thalmann Financial ServicesUpgradeNeutral -> Buy$1.60HighView Rating Details
7/27/2017Chardan CapitalReiterated RatingNeutral$1.50LowView Rating Details
7/26/2017Piper Jaffray CompaniesReiterated RatingHold$1.50LowView Rating Details
7/21/2017Cantor FitzgeraldReiterated RatingHold$2.00LowView Rating Details
1/18/2017FBR & CoReiterated RatingOutperform$12.00N/AView Rating Details
11/11/2016WedbushReiterated RatingNeutral$2.00 -> $1.50N/AView Rating Details
11/10/2016J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
9/16/2016S&P Equity ResearchLower Price Target$1.44 -> $1.17N/AView Rating Details
9/16/2016Citigroup Inc.DowngradeBuy -> Neutral$12.00 -> $1.50N/AView Rating Details
8/29/2016GuggenheimReiterated RatingBuy$25.00N/AView Rating Details
(Data available from 10/20/2015 forward)


Earnings History for Novavax (NASDAQ:NVAX)
Earnings by Quarter for Novavax (NASDAQ:NVAX)
Earnings History by Quarter for Novavax (NASDAQ NVAX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($0.16)($0.16)$6.15 million$6.70 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.18)($0.16)$6.17 million$5.68 millionViewListenView Earnings Details
2/27/2017Q416($0.23)($0.21)$5.45 million$5.40 millionViewListenView Earnings Details
11/9/2016Q316($0.26)($0.24)$4.02 million$3.20 millionViewListenView Earnings Details
8/9/2016Q216($0.25)($0.29)$8.03 million$2.50 millionViewListenView Earnings Details
5/4/2016Q1($0.27)($0.29)$10.39 million$4.20 millionViewListenView Earnings Details
2/29/2016Q415($0.14)($0.29)$8.07 million$5.90 millionViewListenView Earnings Details
11/9/2015Q315($0.09)($0.12)$10.59 million$6.50 millionViewN/AView Earnings Details
8/10/2015Q215($0.09)($0.08)$9.90 million$14.00 millionViewListenView Earnings Details
5/7/2015Q115($0.11)($0.10)$9.70 million$9.88 millionViewN/AView Earnings Details
2/26/2015Q4 14($0.08)($0.13)$9.60 million$6.70 millionViewN/AView Earnings Details
11/5/2014Q314($0.07)($0.08)$9.20 million$8.20 millionViewN/AView Earnings Details
8/6/2014Q214($0.07)($0.08)$8.74 million$8.26 millionViewN/AView Earnings Details
5/7/2014Q114($0.07)($0.07)$3.80 million$7.50 millionViewN/AView Earnings Details
3/10/2014Q413($0.08)($0.07)$6.22 million$8.70 millionViewN/AView Earnings Details
11/7/2013Q313($0.06)($0.09)$4.56 million$4.80 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.06)($0.08)$4.45 million$3.50 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.06)($0.07)$5.54 million$3.80 millionViewN/AView Earnings Details
3/1/2013Q4 2012($0.04)($0.06)$5.85 million$4.57 millionViewN/AView Earnings Details
11/2/2012Q312($0.05)($0.05)$7.59 million$5.80 millionViewN/AView Earnings Details
8/3/2012($0.07)($0.05)ViewN/AView Earnings Details
5/4/2012($0.04)($0.06)ViewN/AView Earnings Details
3/9/2012($0.04)($0.03)ViewN/AView Earnings Details
11/4/2011($0.06)($0.03)ViewN/AView Earnings Details
8/5/2011($0.08)($0.04)ViewN/AView Earnings Details
5/9/2011($0.07)($0.07)ViewN/AView Earnings Details
3/28/2011($0.09)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Novavax (NASDAQ:NVAX)
2017 EPS Consensus Estimate: ($0.66)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.19)($0.17)($0.18)
Q2 20172($0.16)($0.16)($0.16)
Q3 20172($0.17)($0.16)($0.17)
Q4 20172($0.16)($0.14)($0.15)
(Data provided by Zacks Investment Research)


Dividend History for Novavax (NASDAQ:NVAX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Novavax (NASDAQ:NVAX)
Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 45.17%
Insider Trades by Quarter for Novavax (NASDAQ:NVAX)
Institutional Ownership by Quarter for Novavax (NASDAQ:NVAX)
Insider Trades by Quarter for Novavax (NASDAQ:NVAX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/31/2017James F. YoungDirectorSell175,000$1.06$185,500.00View SEC Filing  
7/31/2017Barclay A. PhillipsCFOBuy2,057$0.89$1,830.73View SEC Filing  
5/12/2017Michael A Mcmanus JrDirectorBuy20,000$0.97$19,400.00View SEC Filing  
5/11/2017Barclay A PhillipsCFOBuy25,000$0.84$21,000.00View SEC Filing  
5/11/2017Michael A Mcmanus JrDirectorBuy10,000$0.84$8,400.00View SEC Filing  
5/11/2017Stanley C ErckInsiderBuy50,000$0.84$42,000.00View SEC Filing  
1/31/2017Barclay A. PhillipsCFOBuy1,633$1.12$1,828.96View SEC Filing  
1/31/2017John A. Herrmann IIISVPBuy4,960$1.12$5,555.20View SEC Filing  
12/7/2016Gregory M GlennInsiderBuy1,000$1.45$1,450.00View SEC Filing  
9/22/2016John TrizzinoSVPBuy46,000$2.17$99,820.00View SEC Filing  
9/21/2016Gregory M GlennInsiderBuy1,000$1.65$1,650.00View SEC Filing  
9/21/2016Michael A Mcmanus JrDirectorBuy30,000$1.61$48,300.00View SEC Filing  
9/20/2016Gail BoudreauxDirectorBuy100,000$1.45$145,000.00View SEC Filing  
7/31/2016Barclay A. PhillipsCFOBuy422$4.29$1,810.38View SEC Filing  
6/6/2016Gary C EvansDirectorSell18,998$6.50$123,487.00View SEC Filing  
5/24/2016Gary C EvansDirectorSell50,000$5.41$270,500.00View SEC Filing  
3/31/2016Stanley C ErckCEOSell424,778$5.19$2,204,597.82View SEC Filing  
1/31/2016Barclay A. PhillipsCFOBuy405$4.38$1,773.90View SEC Filing  
1/31/2016Gregory M. GlennSVPBuy2,369$4.38$10,376.22View SEC Filing  
1/31/2016Stanley C. ErckCEOBuy2,072$4.38$9,075.36View SEC Filing  
12/16/2015John A Herrmann IIISVPSell27,945$8.64$241,444.80View SEC Filing  
8/24/2015Gary C EvansDirectorSell20,000$11.24$224,800.00View SEC Filing  
8/20/2015Barclay A. PhillipsCFOSell28,656$13.06$374,247.36View SEC Filing  
8/18/2015Gregory M. GlennSVPSell15,000$13.52$202,800.00View SEC Filing  
8/13/2015Gary C EvansDirectorSell6,002$13.56$81,387.12View SEC Filing  
6/18/2015James F YoungDirectorSell50,000$9.47$473,500.00View SEC Filing  
6/17/2015Rajiv I ModiDirectorSell433,053$9.01$3,901,807.53View SEC Filing  
6/11/2015Rajiv I ModiDirectorSell11,185$9.00$100,665.00View SEC Filing  
6/10/2015Rajiv I ModiDirectorSell551,081$8.97$4,943,196.57View SEC Filing  
6/9/2015Rajiv I ModiDirectorSell47,531$8.93$424,451.83View SEC Filing  
6/8/2015Rajiv I ModiDirectorSell206,175$8.93$1,841,142.75View SEC Filing  
6/4/2015Rajiv I ModiDirectorSell504,681$8.92$4,501,754.52View SEC Filing  
6/1/2015Rajiv I ModiDirectorSell3,500,000$8.74$30,590,000.00View SEC Filing  
1/31/2015Barclay A PhillipsCFOBuy8,388$2.28$19,124.64View SEC Filing  
1/31/2015John TrizzinoSVPBuy6,611$3.63$23,997.93View SEC Filing  
1/31/2015Stanley C ErckCEOBuy6,122$2.28$13,958.16View SEC Filing  
12/16/2014Gary C EvansDirectorSell46,701$5.72$267,129.72View SEC Filing  
12/12/2014Gary C EvansDirectorSell30,000$5.77$173,100.00View SEC Filing  
11/20/2014Rajiv I ModiDirectorSell518,889$5.02$2,604,822.78View SEC Filing  
11/18/2014Rajiv I ModiDirectorSell1,481,111$5.00$7,405,555.00View SEC Filing  
10/3/2014Barclay A PhillipsCFOBuy5,000$4.11$20,550.00View SEC Filing  
10/3/2014Timothy Jon HahnSVPBuy2,500$4.05$10,125.00View SEC Filing  
9/26/2014Gregory M GlennSVPSell16,809$4.16$69,925.44View SEC Filing  
9/25/2014Timothy Jon HahnSVPBuy9,000$4.17$37,530.00View SEC Filing  
7/31/2014Barclay A PhillipsCFOBuy8,788$2.28$20,036.64View SEC Filing  
7/31/2014Russell P WilsonSVPBuy4,989$2.28$11,374.92View SEC Filing  
7/31/2014Stanley C ErckCEOBuy6,788$2.28$15,476.64View SEC Filing  
6/17/2014John TrizzinoSVPBuy5,500$4.51$24,805.00View SEC Filing  
6/16/2014John TrizzinoSVPBuy16,500$4.51$74,415.00View SEC Filing  
3/25/2014Barclay PhillipsCFOBuy5,000$4.25$21,250.00View SEC Filing  
3/25/2014Richard DouglasDirectorBuy50,000$4.33$216,500.00View SEC Filing  
3/25/2014Stanley ErckCEOBuy10,000$4.27$42,700.00View SEC Filing  
3/21/2014Pharmaceuticals Ltd Cadilamajor shareholderSell3,000,000$4.95$14,850,000.00View SEC Filing  
1/31/2014Barclay PhillipsCFOBuy9,868$2.29$22,597.72View SEC Filing  
1/31/2014Stanley ErckCEOBuy11,868$2.29$27,177.72View SEC Filing  
1/31/2014Timothy Jon HahnSVPBuy9,416$2.29$21,562.64View SEC Filing  
6/12/2013Richard DouglasDirectorBuy50,000$1.90$95,000.00View SEC Filing  
6/10/2013Timothy Jon HahnSVPBuy21,000$1.88$39,480.00View SEC Filing  
6/7/2013Gregory M GlennInsiderBuy2,000$1.92$3,840.00View SEC Filing  
6/6/2013James F YoungDirectorBuy100,000$1.91$191,000.00View SEC Filing  
3/11/2013James F YoungDirectorBuy100,000$2.03$203,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Novavax (NASDAQ:NVAX)
Latest Headlines for Novavax (NASDAQ:NVAX)
DateHeadline logoComparing Novavax (NVAX) and Seattle Genetics (SGEN) - October 20 at 2:10 PM logoNovavax, Inc. breached its 50 day moving average in a Bearish Manner : NVAX-US : October 18, 2017 - October 19 at 7:00 AM logoNovavax, Inc. breached its 50 day moving average in a Bearish Manner : NVAX-US : October 18, 2017 - October 19 at 7:00 AM logoNovavax: Down A CFO But Not Out - Seeking Alpha - October 18 at 7:50 AM logoFeatured Company News - Novavax's CFO Resigns - October 17 at 3:21 AM logoNovavax CFO Phillips resigns to pursue other opportunity in the industry - October 14 at 6:18 AM logoNovavax announces a major leadership change - October 14 at 6:18 AM logoNovavax Announces Leadership Change - October 13 at 7:34 AM logoNovavax, Inc. (NVAX) Short Interest Update - October 13 at 1:58 AM logoNovavax, Inc. (NVAX) Receives Consensus Rating of "Hold" from Brokerages - October 11 at 6:36 PM logoToday's Research Reports on Trending Tickers: AVEO Pharmaceuticals and Novavax - October 9 at 3:57 PM logoEquities Analysts Set Expectations for Novavax, Inc.'s FY2017 Earnings (NVAX) - October 9 at 3:16 AM logoNovavax's (NVAX) Neutral Rating Reaffirmed at Seaport Global Securities - October 7 at 2:58 PM logoNovavax: Beware Of The Siren Song - Seeking Alpha - October 5 at 12:48 PM logoHow Should You Think About Novavax Inc’s (NVAX) Risks? - September 30 at 5:40 PM logoContrasting Novavax (NVAX) & Its Peers - September 29 at 6:24 PM logoWhy Novavax, Inc. Could Be a Gold Mine for Growth Investors - Motley Fool - September 24 at 6:26 AM logoWhy Novavax, Inc. Could Be a Gold Mine for Growth Investors - September 23 at 10:50 AM logoBillionaires Are Gobbling Up This Beaten-Down Biotech Stock: Should You? - September 21 at 3:47 PM logoNovavax Initiates Phase 1/2 Trial of NanoFlu™ Vaccine in Older Adults - September 20 at 7:07 AM logoNovavax Initiates Phase 1/2 Trial of NanoFlu(TM) Vaccine in Older Adults - September 20 at 7:07 AM logoNovavax to Present at the Ladenburg Thalmann 2017 Healthcare Conference - September 20 at 7:07 AM logoNovavax, Inc. (NVAX) Receives Average Recommendation of "Hold" from Analysts - September 16 at 6:48 PM logoNovavax: Catalysts Building Toward A Crescendo - Novavax, Inc ... - Seeking Alpha - September 14 at 8:31 AM logoETFs with exposure to Novavax, Inc. : September 6, 2017 - September 6 at 7:01 AM logoFinancial Comparison: Inovio Pharmaceuticals (INO) versus Novavax (NVAX) - September 2 at 4:10 PM logoInsider Selling: Novavax, Inc. (NVAX) Director Sells 175,000 Shares of Stock - September 1 at 8:04 PM logoHead to Head Contrast: Novavax (NVAX) vs. ANI Pharmaceuticals (ANIP) - August 27 at 6:20 AM logoETFs with exposure to Novavax, Inc. : August 25, 2017 - August 26 at 7:51 AM logoBetter Buy: Inovio Pharmaceuticals, Inc. vs. Novavax, Inc. - August 25 at 12:47 PM logoNovavax (NVAX) Reports Publication of Pre-Clinical Influenza Nanoparticle ... - August 24 at 10:18 AM logoNovavax’ Preclinical Influenza Nanoparticle Study Published in Vaccine - August 24 at 10:18 AM logoNovavax (NVAX) Reports Publication of Pre-Clinical Influenza Nanoparticle Study for Nanoparticle Influenza Vaccine ... - - August 23 at 9:23 AM logoNovavax: The Case For Going Long - Seeking Alpha - August 23 at 9:23 AM logoNovavax' Preclinical Influenza Nanoparticle Study Published in Vaccine - August 23 at 9:23 AM logoNovavax, Inc. (NVAX) Given Average Rating of "Hold" by Brokerages - August 22 at 6:50 PM logo3 Top Biotech Stocks Under $10 - August 19 at 1:20 PM logoNovavax, Inc. :NVAX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017 - August 17 at 6:22 AM logoWhy analysts think Novavax's flu vaccine could be a big deal - August 15 at 4:33 PM logoThe Hidden Gem in Novavax's Pipeline You'll Want to Watch - August 15 at 4:33 PM logoThe Hidden Gem in Novavax's Pipeline You'll Want to Watch - August 15 at 3:28 PM logoCan Novavax Stage A Comeback In Q4? One Analyst Thinks So - Benzinga - August 12 at 6:25 AM logoCan Novavax Stage A Comeback In Q4? One Analyst Thinks So - August 12 at 6:25 AM logoNovavax, Inc. (NASDAQ:NVAX) Announces Quarterly Earnings Results, Hits Expectations - August 10 at 4:04 PM logoEARNINGS SUMMARY: Details of Novavax Inc. Q2 Earnings Report - August 10 at 6:22 AM logoEdited Transcript of NVAX earnings conference call or presentation 8-Aug-17 8:30pm GMT - August 10 at 6:22 AM logoNovavax, Inc. (NASDAQ:NVAX) Upgraded to Buy at Ladenburg Thalmann Financial Services - August 9 at 7:40 AM logoNovavax Reaching Critical Mass? - Seeking Alpha - August 9 at 5:35 AM logoInvestor Network: Novavax, Inc to Host Earnings Call - August 9 at 5:35 AM logoNovavax Reports Second Quarter 2017 Financial Results - August 9 at 5:35 AM



Novavax (NVAX) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.